Key Takeaway: The article discusses groundbreaking findings on the elimination and inactivation of cccDNA in liver biopsies from chronic hepatitis B patients treated with PBGENE-HBV. This evidence was presented at the European Association for the Study of the Liver (EASL) Conference, indicating a significant advancement in hepatitis B treatment. The results suggest potential for PBGENE-HBV as a viable therapeutic option.
Price reaction · baseline $7.58 (2026-05-26 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close
+0.1%
day 1 · peak
-8.7%
day 3
-7.4%
Market Sentiment Analysis
POSITIVE FACTORS
First evidence of cccDNA elimination in chronic hepatitis B patients.
Potential breakthrough treatment with PBGENE-HBV.
Promising results presented at a major conference.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
Yuen, MF, et. al. (2026) European Association for the Study of the Liver (EASL) Conference.
The post First evidence of elimination and inactivation of cccDNA in liver biopsies collected from patients with chronic hepatitis B treated with PBGENE-HBV appeared first on Precision BioSciences .
Frequently Asked Questions
What is cccDNA?
cccDNA is a form of viral DNA that persists in the liver during chronic hepatitis B.
What does PBGENE-HBV do?
PBGENE-HBV is a treatment aimed at eliminating cccDNA in patients with chronic hepatitis B.
Where were the findings presented?
The findings were presented at the European Association for the Study of the Liver (EASL) Conference.
What is the significance of this research?
This research provides the first evidence of cccDNA elimination, marking a potential breakthrough in hepatitis B treatment.